von Willebrand disease update: Diagnostic and treatment dilemmas

Haemophilia

Volumn 14, Issue SUPPL. 3, 2008, Pages 56-61

  Bolton Maggs, Paula H B ^a   Lillicrap, D ^b   Goudemand, J ^c   Berntorp, E ^d  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIV LILLE   (France)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diagnosis; Molecular genetics; Prophylaxis study; VWD; VWD Normandy; VWD type 3

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VON WILLEBRAND FACTOR;

ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BLOOD CLOTTING FACTOR DEFICIENCY; CHROMOSOME 12; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG INDICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GENE LOCATION; GENE TRANSFER; GENETIC ANALYSIS; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC LINKAGE; HEMARTHROSIS; HEMOPHILIA A; HUMAN; LINKAGE ANALYSIS; LONG TERM CARE; MENORRHAGIA; MISSENSE MUTATION; MOLECULAR GENETICS; MUCOSAL BLEEDING; ORAL BLEEDING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE TRAIT; SUBSTITUTION THERAPY; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 1; VON WILLEBRAND DISEASE TYPE 2; VON WILLEBRAND DISEASE TYPE 3;

COAGULANTS; DEAMINO ARGININE VASOPRESSIN; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOSTATICS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PHENOTYPE; QUALITY OF LIFE; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 44249103993     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01713.x     Document Type: Article

References (44)

1. von Willebrand E. Hereditär pseudohemofili. Fin Läkaresällsk Handl 1926; 68: 87-112.
2. Nilsson I, Blombäck M, Jorpes E, Johansson S. Von Willebrand′s disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957; 159: 179-188.
3. Federici AB, Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004; 103: 2032-2038.
4. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: Results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16(Suppl. 1): S17-S21.
5. Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-174.
6. Eikenboom J, Van Marion V, Putter H et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 4: 774-782.
7. James PD, Paterson AD, Notley C et al. Genetic linkage and association analysis in type 1 von Willebrand disease: Results from the Canadian type 1 VWD study. J Thromb Haemost 2006; 4: 783-792.
8. Cumming A, Grundy P, Keeney S et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-641.
9. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
10. James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109: 145-154.
11. Davies JA, Collins PW, Hathaway LS, Bowen DJ. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. J Thromb Haemost 2008; 6: 97-103.
12. O'Brien LA, James PD, Othman M et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003; 102: 549-557.
13. Keeney S, Grundy P, Collins PW, Bowen DJ. C1584 in von Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in vitro. Haemophilia 2007; 13: 405-408.
14. Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand J. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 20-26.
15. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-1599.
16. Gaucher C, Jorieux S, Mercier B, Oufkir D, Mazurier C. The "Normandy" variant of von Willebrand disease: Characterization of a point mutation in the von Willebrand factor gene. Blood 1991; 77: 1937-1941.
17. Mazurier CHilbert L. Type 2N von Willebrand disease. Curr Hematol Rep 2005; 4: 350-358.
18. Eikenboom JC, Reitsma PH, Peerlinck KM, Briet E. Recessive inheritance of von Willebrand's disease type I. Lancet 1993; 341: 982-986.
19. Simon D, Roisenberg I. Type 2N von Willebrand disease mutations in Brazilian individuals. Haemophilia 2004; 10: 473-476.
20. Schneppenheim R, Budde U, Krey S et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996; 76: 598-602.
21. Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease - results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1996; 76: 270-274.
22. Castaman G, Eikenboom JC. ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854GIn, and the missense mutation Cys2362Phe. Blood 2002; 100: 1927-1928.
23. Zhang ZP, Lindstedt M, Blomback M, Anvret M. Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995; 1995: 388-394.
24. Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A, Goudemand M. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: Consequences for therapy and genetic counselling. Br J Haematol 1990; 76: 372-379.
25. Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992; 67: 391-396.
26. Lopez-Fernandez MF, Blanco-Lopez MJ, Castineira MP, Batlle J. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII. Am J Hematol 1992; 40: 20-27.
27. Casonato A, Gaucher C, Pontara E et al. Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene. Br J Haematol 1998; 103: 39-41.
28. Miller CH, Kelley L, Green D. Diagnosis of von Willebrand disease type 2N: A simplified method for measurement of factor VIII binding to von Willebrand factor. Am J Hematol 1998; 58: 311-318.
29. Taylor SL, Bromidge E, Savidge GF, Alhaq A. Evaluation of an automated screening assay for von Willebrand disease type 2N. Clin Lab Haematol 2002; 24: 369-375.
30. Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol 2002; 117: 716-718.
31. Jorieux S, Gaucher C, Goudemand J, Mazurier C. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization. Blood 1998; 92: 4663-4670.
32. Schneppenheim R, Lenk H, Obser T et al. Recombinant expression of mutations causing von Willebrand disease type Normandy: Characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004; 92: 36-41.
33. Hilbert L, Nurden P, Caron C et al. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb Haemost 2006; 96: 290-294.
34. Castaman G, Novella E, Contino L, Demicheli M, Rodeghiero F. First Italian families with homozygous R854Q type 2N von Willebrand disease. Thromb Haemost 2002; 88: 534-535.
35. Castaman G, Bertoncello K, Bernardi M, Rodeghiero F. Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease. J Thromb Haemost 2005; 3: 391-392.
36. Nishino M, Nishino S, Sugimoto M, Shibata M, Tsuji S, Yoshioka A. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy. Int J Hematol 1996; 64: 127-134.
37. Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group. Br J Haematol 1994; 88: 849-854.
38. Goudemand J, Scharrer I, Berntorp E et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005; 3: 2219-2227.
39. Dennis MW, Clough V, Toh CH. Unexpected presentation of type 2N von Willebrand disease in pregnancy. Haemophilia 2000; 6: 696-697.
40. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-1239.
41. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 2006; 32: 621-625.
42. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16(Suppl. 1): S23-S26.
43. Berntorp E, Abshire T. The von Willebrand disease prophylaxis network (vWD PN): Exploring a treatment concept. Thromb Res 2006; 118(Suppl. 1): S19-S22.
44. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: Where do we stand? Haemophilia 2004; 10(Suppl. 4): 97-104.